PUBLISHER: 360iResearch | PRODUCT CODE: 1465050
PUBLISHER: 360iResearch | PRODUCT CODE: 1465050
[187 Pages Report] The Binge Eating Disorder Market size was estimated at USD 556.42 million in 2023 and expected to reach USD 587.85 million in 2024, at a CAGR 5.98% to reach USD 835.76 million by 2030.
Binge eating disorder (BED) is recognized as an eating disorder described by recurrent episodes of consuming large quantities of food, often quickly, accompanied by a feeling of loss of control during the bingeing and experiencing shame, distress, or guilt afterward. It differs from overeating in its frequency and severity, and it's classified as a significant mental health condition requiring attention. A growing awareness and understanding of BED as a significant health issue have led to more people seeking treatment. Additionally, advancements in treatment options, including cognitive behavioral therapy (CBT), medications, and personalized therapy sessions, have provided effective means for management, acting as a significant driver for the binge eating disorder market. Despite the growth prospects, a lack of awareness and the stigma associated with mental health and eating disorders hinders individuals from seeking treatment. Moreover, the high cost of therapy and lack of insurance coverage in some areas pose significant barriers to accessing effective treatment options. However, the integration of advanced technology in treatment processes, such as telehealth services and mobile applications for self-management, offers new ways to support individuals in remote or underserved locations. Additionally, ongoing research and development are leading to novel therapeutic drugs and interventions, expanding the range of treatment options available.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 556.42 million |
Estimated Year [2024] | USD 587.85 million |
Forecast Year [2030] | USD 835.76 million |
CAGR (%) | 5.98% |
Product: Need for efficient diagnosis to accurately identify BED and any comorbid conditions
The diagnostics segment for binge eating disorder primarily involves psychological evaluations, physical exams, and laboratory tests. Accurate and early diagnostic tools are crucial for understanding the patient's eating behaviors, history, and mental health status.
The treatment segment for binge eating disorder comprises pharmacotherapy, psychotherapy, and support groups/counseling. Anticonvulsants, such as topiramate, stabilize mood and possibly reduce food cravings through modulation of neurotransmitter pathways in the brain. Antidepressants, including selective serotonin reuptake inhibitors (SSRIs), are commonly used in the treatment of BED, reflecting the comorbidity of BED with mood disorders. The effectiveness of antidepressants in treating BED is theorized to come from their ability to increase serotonin levels, which may influence mood and potentially reduce compulsive eating behaviors. Cognitive behavioral therapy (CBT) focuses on identifying and changing negative thought patterns and behaviors related to binge eating. CBT helps individuals develop coping strategies to control urges to binge, improve self-esteem, and address co-occurring psychological issues such as depression or anxiety. Dialectical behavior therapy (DBT) is a form of cognitive-behavioral therapy that integrates strategies for mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness. Its primary focus in BED treatment is helping individuals understand and accept their binge-eating behaviors while simultaneously working on changing these behaviors by building coping skills. Interpersonal psychotherapy (IPT) is a time-limited treatment focused on improving interpersonal functioning and communication skills. It explores underlying interpersonal issues that may trigger binge eating episodes, such as unresolved grief, role disputes, role transitions, and interpersonal deficits.
End-User: Higher preferences for hospitals with comprehensive services, essential for addressing the complex needs of BED patients
Hospitals have a crucial role in the treatment and management of binge eating disorder (BED). As end-users, hospitals adopt a multidisciplinary approach to provide comprehensive care, including medical evaluation, nutritional counseling, psychiatric support, and behavioral therapies. Hospitals are preferred for their capacity to offer immediate medical care combined with follow-up treatment plans. Specialty clinics focused on eating disorders offer targeted and personalized care for individuals with binge eating disorders. These clinics provide an array of specialized treatment options, including cognitive-behavioral therapy (CBT), interpersonal psychotherapy (IPT), dialectical behavior therapy (DBT), and medication management tailored specifically to BED. The specialized nature of these clinics allows for a deeper understanding of the disorder, fostering an environment where patients can receive focused care from professionals highly experienced in treating eating disorders.
Regional Insights
In the Americas, increasing awareness and diagnosis of binge eating disorder has resulted in significant adoption of both pharmacological and non-pharmacological treatments, which has led to a robust market performance in this region. The FDA's approval of medications specific to BED and coverage of therapy sessions by insurance companies contribute to the growth. In the EMEA region, the market performance is influenced by a growing awareness of BED as a distinct medical condition. Europe, with advanced healthcare systems and widespread availability of treatment options, including cognitive behavioral therapy (CBT), has been contributing majorly to the growth of EMEA's binge eating disorder market. The Middle East and Africa, however, exhibit slower growth owing to limited awareness and healthcare infrastructure. The APAC region is witnessing a gradual increase in the recognition of binge eating disorder and its treatment market, driven by the rise of mental health awareness. However, the region faces challenges such as cultural stigmas around mental health and a paucity of specialized healthcare providers.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Binge Eating Disorder Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Binge Eating Disorder Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Binge Eating Disorder Market, highlighting leading vendors and their innovative profiles. These include Alsana, Inc., Alvogen, Amneal Pharmaceuticals, Inc., Apotex Inc., Ascent Pharmaceuticals, Inc., BALANCE Eating Disorder Treatment Center, Carolina House Eating Disorder Treatment Center, Center for Change, Eating Disorders Treatment Center, Eating Recovery Center, Equip Health Medical, P.C., Hikma Pharmaceuticals PLC, Mallinckrodt PLC, Monte Nido & Affiliates Holdings, LLC, Montecatini Eating Disorder Treatment Center, Natural Food Therapy, Red Oak Recovery, Rhodes Pharmaceuticals L.P. by Purdue Pharma L.P., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, TalktoAngel, The London Centre for Eating Disorders and Body Image Ltd., Timberline Knolls Residential Treatment Center, Veritas Collaborative, and Viatris Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Binge Eating Disorder Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Binge Eating Disorder Market?
3. What are the technology trends and regulatory frameworks in the Binge Eating Disorder Market?
4. What is the market share of the leading vendors in the Binge Eating Disorder Market?
5. Which modes and strategic moves are suitable for entering the Binge Eating Disorder Market?
T